Brief: Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan)
04/06/2026 09:31
BRIEF-Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan) June 4 (Reuters) - Innovent Biologics Inc 1801.HK:
NMPA ACCEPTS NDA FOR IBI343 (ARCOTATUG TAVATECAN) FOR ADVANCED GASTRIC CANCER
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis